亚宝药业: 亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告

Group 1 - The company announced a share repurchase plan with a proposed amount of 50 million to 100 million RMB, aimed at reducing registered capital [1][2] - The repurchase period is set from May 16, 2025, to November 14, 2025, following the approval from the shareholders' meeting [1][2] - As of August 31, 2025, the company has repurchased a total of 200,000 shares, representing 0.03% of the total share capital, at a total cost of 1,260,000 RMB [2] Group 2 - The repurchase price was consistent at 6.30 RMB per share, indicating a stable market price during the repurchase period [2] - The company will continue to comply with relevant regulations and disclose progress on the share repurchase in a timely manner [2]